🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Danirixin

Found 15 matching trials

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

PHASE1

This will be the first time GSK1325756 Solution for Infusion formulation th...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-06-12

Trial ID

NCT02169583

Treatments Being Tested

GSK1325756 Solution GSK1325756 Solution Matching Placebo GSK1325756 Tablet GSK1325756 Tablet Matching Placebo

Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

Danirixin (DNX) is a selective CXC chemokine receptor (CXCR2) antagonist be...

Status

Completed

Location

GSK Investigational Site

Start Date

2017-04-25

Trial ID

NCT03034967

Treatments Being Tested

Danirixin Danirixin matching placebo Standard of care Rescue medication

A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

This is a pilot study to investigate the effect of danirixin hydrobromide 3...

Status

Terminated

Location

GSK Investigational Site

Start Date

2017-10-16

Trial ID

NCT03170232

Treatments Being Tested

Danirixin 35 mg tablets Placebo Metered dose inhaler (MDI) sensor device Rescue medication

Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression

PHASE1

This study is to determine danirixin (GSK1325756) concentrations required t...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-01-13

Trial ID

NCT02201303

Treatments Being Tested

Danirixin CXCL1

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

PHASE2

The aim of this First Time in Patient study is to obtain initial informatio...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-02-13

Trial ID

NCT02130193

Treatments Being Tested

Danirixin Placebo

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

PHASE2

Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X...

Status

Terminated

Location

GSK Investigational Site

Start Date

2017-01-19

Trial ID

NCT02927431

Treatments Being Tested

Danirixin 15 mg FBE Danirixin 50 mg FBE Placebo Oseltamivir 75 mg

First Time in Human Study With GSK1325756

PHASE1

This study aims to investigate the safety, tolerability, pharmacokinetics a...

Status

Completed

Location

GSK Investigational Site

Start Date

2009-10-15

Trial ID

NCT01209052

Treatments Being Tested

GSK1325756 Placebo

A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole

PHASE1

The current study will help to increase our understanding of the pharmacoki...

Status

Completed

Location

GSK Investigational Site

Start Date

2015-05-18

Trial ID

NCT02453022

Treatments Being Tested

Danirixin HBr 50 mg IR Tablet Danirixin FB 50 mg IR Tablet Prilosec (omeprazole) 40mg Delayed-Release capsule

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

PHASE1

GSK1325756 is a potent, competitive, selective and reversible CXCR2 recepto...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-04-14

Trial ID

NCT01209104

Treatments Being Tested

GSK1325756 GSK1325756

A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced

PHASE1

This is a Phase I study to assess the combined effects of food and suppress...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-10-12

Trial ID

NCT01453478

Treatments Being Tested

GSK1325756

Previous Next